The true function of medication adherence brought to life in kidney

Underdose and there is a risk of rejection; overdose and there is a risk of cancer.

Kidneys are the most frequently transplanted organ, and as such, the?rate of kidney transplants worldwide?has increased over the past few years reaching 17.1 transplants per million population in 2022, compared to a rate of 11.1 per million population in 2012. In 2022, there were a?total of 102,090 kidney transplants worldwide[1].

?

Thanks to the advancement in surgical procedures, many people lead healthy, fulfilling lives after their kidney transplant. Indeed, the first-year kidney transplant survival rate is 95% and the average three-to-five-year survival rate is 90%. However, a kidney transplant is a major operation and comes with risks. Infections are common after a kidney transplant and a regimen of immunosuppressant medications are required to prevent the body from rejecting the new organ.

As a study published in 2019 has demonstrated, non-adherence to post transplant immunosuppressive medication is associated with increased rates of rejection and graft loss[2]. Conversely, the study also questioned whether excellent adherence increased the risk of post-transplant cancer.

?

In an eight-year period, 195 kidney transplant recipients participated in the electronic monitoring of their immunosuppressive medication adherence. The results were stark – the estimated cumulative cancer incidence was 59.4% in the most adherent group, compared with 38.1% in the least adherent group.

?

The conclusion was equally sharply defined. That medication needs to be individualised in order to minimise both rejection and drug-related complications including cancer.

?

Within this context, the establishment of an optimal dose seems clear and obvious: to arrive at a clear dose volume which, when taken faithfully by patients, will deliver the desired target level of exposure.

?

Too often, dosing levels are frequently set above optimal levels. This is often motivated by the objective of maximising efficacy, but without sufficient robust dose-response data, the risk remains that patients are subjected to excessive levels of toxicity.??

?

In reality the only way to optimise the dose is to establish accurate measures of dose exposure and response early on at clinical trial stage. And that’s where we come in.??

?

Establishing hard evidence for your trial…???

AARDEX has a best practice methodology, independent of any device package or software platform. Utilising our expertise and experience in medication adherence and patient compliance we acquire, monitor, analyse, guide and interpret data to deliver absolute clarity and bring confidence to sponsors, trialists, and ultimately, patients.????

?

AARDEX is the only mature, robust and proven adherence solution on the market today, one that maximises the reward, mitigates the risk and delivers resolution for your clinical trial. All delivered with the clarity, integrity and certainty you need to proceed with complete confidence in the exposure-response.????

[1] https://www.statista.com/statistics/398657/kidney-transplants-by-world-region/#:~:text=The%20rate%20of%20kidney%20transplants,of%20102%2C090%20kidney%20transplants%20worldwide.

[2] https://pubmed.ncbi.nlm.nih.gov/30102328/